阅读说明：本技术 一种抑制结直肠癌转移的组合物及其应用 (Composition for inhibiting colorectal cancer metastasis and application thereof ) 是由 陈文斌 王赛赛 姚圆圆 费儒杉 于 2019-09-16 设计创作，主要内容包括：本发明提供了一种抑制结直肠癌转移的组合物及其应用。本发明组合物主要由5-氟尿嘧啶和胞嘧啶阿糖胞苷组成,优选摩尔比为1:4；用于制备抗结直肠癌药物。本发明组合物能提高巨噬细胞α7烟碱类乙酰胆碱受体(α7nChR)表达量,抑制结直肠癌转移的作用,具有良好的实际应用前景。(The invention provides a composition for inhibiting colorectal cancer metastasis and application thereof. The composition mainly comprises 5-fluorouracil and cytosine arabinoside, and the preferable molar ratio is 1: 4; can be used for preparing medicine for treating colorectal cancer. The composition can improve the expression level of macrophage alpha 7 nicotinic acetylcholine receptor (alpha 7nChR) and inhibit the colorectal cancer metastasis, and has good practical application prospect.)

1. A composition for inhibiting metastasis in colorectal cancer, the composition consisting essentially of 5-fluorouracil and cytosine arabinoside.

2. The composition for inhibiting colorectal cancer metastasis according to claim 1, wherein the molar ratio of 5-fluorouracil to cytosine arabinoside is 1:3 to 1: 5.

3. Use of a composition for inhibiting colorectal cancer metastasis according to claims 1-2, characterized in that the composition is used for the preparation of anti-cancer drugs and other uses for the treatment of cancer.

4. The use of the composition for inhibiting metastasis of colorectal cancer according to claim 3, wherein the anticancer drug is an injection, an oral liquid, a tablet or a capsule.

5. The use of a composition for inhibiting metastasis of colorectal cancer according to claim 3, wherein the use of the anticancer drug for inhibiting metastasis of cancer is disclosed.

6. The use of a composition for inhibiting metastasis of colorectal cancer according to claim 3, wherein the anticancer agent enhances the ability of macrophages to fight cancer cells by increasing the expression level of α 7nChR on macrophages.

7. Use of a composition for inhibiting metastasis of colorectal cancer according to claim 3, wherein the cancer is colorectal cancer.

Technical Field

The invention belongs to the field of biological pharmacy, and particularly relates to a composition for inhibiting colorectal cancer metastasis and application thereof.

Background

Colorectal cancer is one of the most common malignant tumors worldwide, the development speed of China is increased in recent years, the living standard of people is improved, the dietary structure is changed, and the morbidity and the mortality of colorectal cancer in nearly ten years of China are in a rising trend. Approximately half of patients with colorectal cancer develop tumor metastases, with metastasis characterized by poor prognosis and a low 5-year survival rate. The existing antitumor chemotherapeutic drugs mainly act on different links of tumor cell growth and reproduction to inhibit or kill the tumor cells. But the action is not specific, and the normal tissue cells can be killed and killed at the same time. A number of side effects may result from the use of chemotherapeutic drugs, such as alopecia, bone marrow suppression, gastrointestinal reactions, liver and kidney damage, and the like. What is needed is a therapeutic approach to slow the progression of colorectal cancer that is effective and low-toxicity.

Tumor-associated macrophages, the most common immune cells within the tumor microenvironment, can be divided into two parts, one part being tumor-resident macrophages and the other part originating from circulating monocytes recruited to the tumor site by recognizing chemical signals released by the tumor cells or the tumor microenvironment, both of which coexist in the tumor. The cell function of tumor-associated macrophages is edited into different types under physiological and nonpathological conditions, and can promote and resist tumors. It has been shown that tumor-associated macrophages can alter the composition, structure and elasticity of the extracellular matrix and the function of associated factors, affecting the migration of tumor cells.

Acetylcholine is produced by a neurotransmitter in various cells of the body, and is specifically bound with acetylcholine receptors on the surfaces of effector cells through an autocrine or paracrine effect to start a downstream signal pathway, thereby regulating the occurrence of the effect. α 7nChR is a subtype of nicotinic acetylcholine receptors. The influence of the alpha 7nChR on colorectal cancer migration has been reported, and the research shows that the expression of the alpha 7nChR of tumor-associated macrophages can negatively regulate the metastasis of colorectal cancer cells through pathological data and in vitro experimental data. The alpha 7nChR of the macrophage can be a new target point for preventing and treating the metastatic colorectal cancer. At present, no report that the composition of 5-fluorouracil and cytosine arabinoside is applied to the alleviation of colorectal cancer cell metastasis through a mechanism of increasing the expression of alpha 7nChR on macrophages exists at home and abroad.

Disclosure of Invention

In order to solve the problems in the background art, the invention provides a composition for inhibiting colorectal cancer metastasis and application thereof, wherein the composition is used for slowing down colorectal cancer cell metastasis by increasing the expression of alpha 7nChR on macrophages.

The technical scheme adopted by the invention is as follows:

composition for inhibiting colorectal cancer metastasis

The composition mainly comprises 5-fluorouracil and cytosine arabinoside.

The molar ratio of the 5-fluorouracil to the cytosine arabinoside is 1: 3-1: 5, and preferably 1: 4.

Application of composition for inhibiting colorectal cancer metastasis

The composition is used for preparing anti-cancer drugs and other applications for treating cancers.

The anticancer drug is injection, oral liquid, tablet or capsule.

The application and the application of the anti-cancer drug in inhibiting cancer metastasis.

The anti-cancer drug enhances the anti-cancer cell capacity of macrophages by improving the expression level of alpha 7nChR on the macrophages.

The cancer is colorectal cancer.

The dosage of the anticancer drug can be adjusted according to the characteristics of the dosage form, the age and the physiological state of a patient.

The invention has the beneficial effects that:

the composition of the invention has obvious difference with the existing antitumor drug in action mechanism.

1) The composition of the invention does not directly act on tumor cells to inhibit proliferation, but indirectly enhances the capability of macrophages for resisting colorectal tumor cells by improving the expression level of alpha 7nChR on the macrophages, thereby playing a role in inhibiting colorectal tumor metastasis.

2) The dosage of the antitumor drug in the composition is less than that of the existing antitumor drug, so that the side effect of the antitumor drug on colorectal tumor patients is reduced.

Detailed Description

The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto.